Nls pharmaceutics announces selection of strategic partner and securing a bridge loan

Nls has executed a non-binding term sheet for licensing of nls intellectual property nls has secured an additional bridge loan through insiders to extend cash runway nls has implemented significant internal cost reductions zurich, switzerland / accesswire / november 16, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it is conducting an ongoing process to explore strategic alternatives to maximize shareholder value.
NLSP Ratings Summary
NLSP Quant Ranking